Publication
Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation
Journal Paper/Review - Sep 1, 2005
Waeckerle-Men Ying, Allmen Edith Uetz-von, von Moos Roger, Classon Brendan J, Scandella Elke, Schmid Hans-Peter, Ludewig Burkhard, Groettrup Marcus, Gillessen Sommer Silke
Units
PubMed
Doi
Citation
Type
Journal
Publication Date
Issn Print
Pages
Brief description/objective
BACKGROUND: Dendritic cell (DC)-based vaccination has been investigated as immunotherapy for several types of cancer. A potential drawback to vaccination with autologous monocyte-derived DCs (MoDCs) could be that MoDCs from patients are functionally impaired. In case of androgen-independent prostate cancer (CaP), the cancer itself, diverse prior therapies, and the hormone manipulation may affect the immune system. METHODS: MoDCs from patients suffering from androgen-independent CaP were generated according to a clinically applicable protocol to evaluate the phenotype, maturation capacity, migration, and T-cell stimulation of these cells compared with those generated from tumor-free donors. RESULTS: MoDCs generated from CaP patients could be fully matured and efficiently migrated towards the chemokine CCL21. They had a strong potency to activate allogeneic CD4+ and CD8+ T-cells and to present antigens to specific CTL. CONCLUSIONS: Our data suggest that MoDCs from patients with androgen-independent CaP are functionally intact and hence qualify as cellular vaccines for immunotherapy of advanced stage CaP.